These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

275 related items for PubMed ID: 24692179

  • 21. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation.
    Holbro T, Beerli RR, Maurer F, Koziczak M, Barbas CF, Hynes NE.
    Proc Natl Acad Sci U S A; 2003 Jul 22; 100(15):8933-8. PubMed ID: 12853564
    [Abstract] [Full Text] [Related]

  • 22. Computational modeling of ERBB2-amplified breast cancer identifies combined ErbB2/3 blockade as superior to the combination of MEK and AKT inhibitors.
    Kirouac DC, Du JY, Lahdenranta J, Overland R, Yarar D, Paragas V, Pace E, McDonagh CF, Nielsen UB, Onsum MD.
    Sci Signal; 2013 Aug 13; 6(288):ra68. PubMed ID: 23943608
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Suppression of heregulin β signaling by the single N-glycan deletion mutant of soluble ErbB3 protein.
    Takahashi M, Hasegawa Y, Ikeda Y, Wada Y, Tajiri M, Ariki S, Takamiya R, Nishitani C, Araki M, Yamaguchi Y, Taniguchi N, Kuroki Y.
    J Biol Chem; 2013 Nov 15; 288(46):32910-21. PubMed ID: 24097984
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3.
    McDonagh CF, Huhalov A, Harms BD, Adams S, Paragas V, Oyama S, Zhang B, Luus L, Overland R, Nguyen S, Gu J, Kohli N, Wallace M, Feldhaus MJ, Kudla AJ, Schoeberl B, Nielsen UB.
    Mol Cancer Ther; 2012 Mar 15; 11(3):582-93. PubMed ID: 22248472
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
    Motoyama AB, Hynes NE, Lane HA.
    Cancer Res; 2002 Jun 01; 62(11):3151-8. PubMed ID: 12036928
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Effects of the combined blockade of EGFR and ErbB-2 on signal transduction and regulation of cell cycle regulatory proteins in breast cancer cells.
    D'Alessio A, De Luca A, Maiello MR, Lamura L, Rachiglio AM, Napolitano M, Gallo M, Normanno N.
    Breast Cancer Res Treat; 2010 Sep 01; 123(2):387-96. PubMed ID: 19946741
    [Abstract] [Full Text] [Related]

  • 36. Modular anti-EGFR and anti-Her2 targeting of SK-BR-3 and BT474 breast cancer cell lines in the presence of ErbB receptor-specific growth factors.
    Diermeier-Daucher S, Breindl S, Buchholz S, Ortmann O, Brockhoff G.
    Cytometry A; 2011 Sep 01; 79(9):684-93. PubMed ID: 21786419
    [Abstract] [Full Text] [Related]

  • 37. Heregulin induces transcriptional activation of the progesterone receptor by a mechanism that requires functional ErbB-2 and mitogen-activated protein kinase activation in breast cancer cells.
    Labriola L, Salatino M, Proietti CJ, Pecci A, Coso OA, Kornblihtt AR, Charreau EH, Elizalde PV.
    Mol Cell Biol; 2003 Feb 01; 23(3):1095-111. PubMed ID: 12529413
    [Abstract] [Full Text] [Related]

  • 38. ERBB3 (HER3) is a key sensor in the regulation of ERBB-mediated signaling in both low and high ERBB2 (HER2) expressing cancer cells.
    Choi BK, Fan X, Deng H, Zhang N, An Z.
    Cancer Med; 2012 Aug 01; 1(1):28-38. PubMed ID: 23342251
    [Abstract] [Full Text] [Related]

  • 39. Induction or suppression of expression of cytochrome C oxidase subunit II by heregulin beta 1 in human mammary epithelial cells is dependent on the levels of ErbB2 expression.
    Sun Y, Lin H, Zhu Y, Ma C, Ye J, Luo J.
    J Cell Physiol; 2002 Aug 01; 192(2):225-33. PubMed ID: 12115729
    [Abstract] [Full Text] [Related]

  • 40. Heregulin-β1-induced GPR30 upregulation promotes the migration and invasion potential of SkBr3 breast cancer cells via ErbB2/ErbB3-MAPK/ERK pathway.
    Ruan SQ, Wang ZH, Wang SW, Fu ZX, Xu KL, Li DB, Zhang SZ.
    Biochem Biophys Res Commun; 2012 Apr 06; 420(2):385-90. PubMed ID: 22425775
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.